ELCC 2016 | Phase 1b trial of CRS-207 with chemotherapy for malignant pleural mesothelioma

David Carbone

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses a phase 1b trial of the anti-mesothelin vaccine CRS-207 plus chemotherapy as frontline treatment for malignant pleural mesothelioma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter